FRANKLIN LAKES, N.J., Nov. 9, 2020 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the expanded role of Tony Ezell as president of North America and chief marketing officer, effective October 1.
Ezell joined BD as chief marketing officer in January of 2020. In his expanded role, he will lead the U.S. and Canada regions and the Global Marketing organization. Ezell succeeds Jamie Condie, who retired as president of the U.S. and Canada regions.
“Bringing together our global marketing and U.S. commercial teams under Tony’s leadership will better align and integrate BD’s approach to how the company addresses and prioritizes customer needs,” said Tom Polen, chief executive officer and president of BD. “His deep understanding of industry market trends, passion for the customer and strong performance as a sales, marketing and business leader prepare him well for this expanded role.”
Quest Imaging Solutions provides all major brands of surgical c-arms (new and refurbished) and carries a large inventory for purchase or rent. With over 20 years in the medical equipment business we can help you fulfill your equipment needs
Prior to BD, Ezell spent more than 27 years at Eli Lilly and Co., where he demonstrated success in sales, marketing and business leadership roles, having led global market research before assuming the role of chief customer officer. He went on to serve as chief marketing officer for Lilly’s Elanco Animal Health business prior to its spinoff and then was the business unit leader for Lilly’s U.S. Connected Care and Insulins business. He holds an MBA from Kellogg School of Management at Northwestern and a Bachelor of Science degree in business from Florida A&M University.
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com.
Back to HCB News